NIOSH Conformity Assessment Letter to Manufacturers
Updated August 21, 2020
This notice has been superseded. For the latest NIOSH guidance on this topic, please see the updated notice: https://www.cdc.gov/niosh/npptl/resources/pressrel/letters/conformitymanuf/CA-2020-1031.html
NIOSH CA 2020-1027
In response to the nation’s effort to control the spread of coronavirus disease 2019 (COVID-19) outbreak, the National Institute for Occupational Safety and Health (NIOSH) Respirator Approval Program is accepting and prioritizing applications received for new approvals and extension of approvals submitted by existing approval holders and new domestic respirator manufacturers/applicants.
NIOSH is committed to protecting healthcare personnel and Americans preparing to return to work by accepting and expediting applications to increase the supply of NIOSH-approved particulate filtering (air-purifying) respirators and ensure quality products providing the intended protections are available. The applications accepted can include those seeking or modifying approval for filtering facepiece respirators (FFR), half mask and full facepiece air-purifying respirators (APR) and powered air-purifying respirators (PAPR). During the response, NIOSH is not accepting applications for approval of FFRs with novel head suspensions, e.g. ear loops.
Once approved, the respirators will be added to the NIOSH Certified Equipment List and will thus be covered under the FDA’s clarification letter and Emergency Use Authorization (EUA), dated March 28, 2020, and for use by healthcare personnel.
NIOSH is also prioritizing Quality Assurance (QA) applications to facilitate FFR, APR, and PAPR production at additional manufacturing sites, in accordance with established and NIOSH-approved QA systems.
NIOSH is also developing procedures to conduct virtual domestic site qualification evaluations of new domestic manufacturing and quality management facilities, for applicants seeking their first NIOSH approval for an FFR, APR or PAPR.
The prioritization of domestic requests will impact NIOSH’s ability to process requests received from new international respirator manufacturer for manufacturers codes, application and engineering reviews and related questions. Additionally, due to heightened concerns over counterfeiting, NIOSH will not respond to emails that lack recognizable company domains. Examples include emails that look like email@example.com, or firstname.lastname@example.org, or email@example.com. Inquiries for approval will only be responded to when received from an email address recognizably associated with a legitimate business or stakeholder.
FDA EUAs NOT Associated with NIOSH Approved Respirators
The FDA Emergency Use Authorizations website should be checked for the most up-to-date information. As of April 23, 2020, the FDA has issued three EUA’s that do NOT require seeking NIOSH approval, NIOSH asks stakeholders interested in inclusion in these authorizations read and follow the information and guidance provided by the FDA.
For inclusion in Exhibit 1 Authorized Respirators:
Manufacturers of Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators; https://www.fda.gov/media/136403/download March 28, 2020, Imported other than China
For inclusion in Appendix A:
Manufacturers of Imported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators; https://www.fda.gov/media/136664/download April 3, 2020, Imported China
Manufacturers of Face Mask:
https://www.fda.gov/media/137121/download April 18, 2020, Facemasks, non-surgical